We have located links that may give you full text access.
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.
International Journal of Eating Disorders 2017 April
OBJECTIVE: Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target.
METHODS: Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program.
RESULTS: The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment.
DISCUSSION: The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.
METHODS: Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program.
RESULTS: The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment.
DISCUSSION: The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app